newsfilter
← Latest News
GlobeNewswire·

Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights

On track to report interim clinical data for two lead programs, PBGM01 for GM1 gangliosidosis and PBFT02 for frontotemporal dementia (FTD), in 2023Submitted protocol amendment to regulatory authorities for Imagine-1